Download PDF
PiD - Psychotherapie im Dialog 2021; 22(03): 44-48
DOI: 10.1055/a-1215-1638
Aus der Praxis

Antidepressiva – wirksam und gut verträglich?

Martin Plöderl
,
Thorsten Padberg
› Further Information
Also available at
    Permissions and Reprints

Die psychopharmakologische Behandlung von Depressionen mit Antidepressiva ist gemäß den Leitlinien empfohlen, zumindest für mittlere bis schwere Depressionen, und die Verschreibung hat sich in im neuen Jahrtausend in Deutschland fast verdreifacht ([ Abb. 1 ]). Demgegenüber steht eine anhaltende Debatte über deren Wirksamkeit und Risiken. Diese sollen im Beitrag unter Berücksichtigung aktueller Evidenz kritisch beleuchtet werden.



Publication History

Article published online:
27 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Leyburn P. A critical look at antidepressant drug trials. Lancet 1967; 290: 1135-1138
    CrossrefPubMedSearch in Google Scholar
  • 2 Kirsch I, Moore TJ, Scoboria A. et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 2002; 5: 23a
    PubMedSearch in Google Scholar
  • 3 Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. Philos Ethics Humanit Med 2008; 3: 14
    CrossrefPubMedSearch in Google Scholar
  • 4 DGPPN. S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression – Langfassung. 2. Aufl., 5. Version. 2015
    PubMedSearch in Google Scholar
  • 5 Cipriani A, Furukawa TA, Salanti G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357-1366
    CrossrefPubMedSearch in Google Scholar
  • 6 Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open 2019; 9: e024886
    CrossrefPubMedSearch in Google Scholar
  • 7 Hengartner MP, Plöderl M. Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that antidepressants work: Effect size and method bias matter!. Front Psy 2018; 9: 517
    CrossrefPubMedSearch in Google Scholar
  • 8 Jakobsen JC, Katakam KK, Schou A. et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017; 1: 162
    CrossrefPubMedSearch in Google Scholar
  • 9 Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder?. BMJ Evid-Based Med 2020; 25: 130 1–6
    CrossrefPubMedSearch in Google Scholar
  • 10 Plöderl M, Hengartner MP. Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry 2019; 19: 265
    CrossrefPubMedSearch in Google Scholar
  • 11 Cipriani A, Zhou X, Del Giovane C. et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388: 881-890
    CrossrefPubMedSearch in Google Scholar
  • 12 Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid-Based Med. 2021 in press
    PubMedSearch in Google Scholar
  • 13 Jureidini J, McHenry LB. The Illusion of Evidence based Medicine. Exposing the Crisis of Credibility in clinical Research. South Australia: Wakefield Press; 2020
    Search in Google Scholar
  • 14 Hengartner MP. Methodological flaws, conflicts of interest, and scientific fallacies: implications for the evaluation of antidepressants’ efficacy and harm. Front Psy 2017; 8
    PubMedSearch in Google Scholar
  • 15 SALSEX Working Study Group. A real-world study on antidepressant-associated sexual dysfunction in 2144 outpatients: The SALSEX I study. Arch Sex Behav 2019; 48: 923-933
    CrossrefPubMedSearch in Google Scholar
  • 16 Serretti A, Chiesa A. Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. J Clin Psychopharmacol 2009; 29: 259-266
    CrossrefPubMedSearch in Google Scholar
  • 17 Hogan C, Le Noury J, Healy D. et al. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med 2014; 26: 109-116
    CrossrefPubMedSearch in Google Scholar
  • 18 Plöderl M. Antidepressiva in der Suizidprävention. Eine kritische Bestandsaufnahme. Suizidproph 2019; 46: 53-64
    PubMedSearch in Google Scholar
  • 19 Plöderl M, Hengartner MP, Bschor T. et al. Commentary to „antidepressants and suicidality: A re-analysis of the re-analysis“. J Affect Disord 2020; 273: 252-253
    CrossrefPubMedSearch in Google Scholar
  • 20 Hengartner MP, Amendola S, Kaminski JA. et al. Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health. 2021 in press
    PubMedSearch in Google Scholar
  • 21 Massabki I, Abi-Jaoude E. Selective serotonin reuptake inhibitor ‘discontinuation syndrome‘ or withdrawal. Br J Psychiatry 2021; 218: 168-171
    CrossrefPubMedSearch in Google Scholar
  • 22 Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?. Addict Behav 2018; 97: 111-121
    CrossrefPubMedSearch in Google Scholar
  • 23 Hengartner MP, Plöderl M. Does antidepressant maintenance therapy prevent relapses or withdrawal reactions? An analysis of time-to-event data from relapse prevention trials. Zur Publikation eingereicht..
    PubMed
  • 24 Hengartner MP. How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychophar 2020; 10: 204512532092169
    CrossrefPubMedSearch in Google Scholar
  • 25 Fava GA. May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Ther Adv Psychophar 2020; 10: 204512532097032
    CrossrefPubMedSearch in Google Scholar
  • 26 Plöderl M, Hengartner MP. Antidepressiva wirken! Oder doch nicht?. Skeptiker 2019; 2: 71-78
    PubMedSearch in Google Scholar
  • 27 Plöderl M, Hengartner MP. What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis. BMJ Open 2019; 9: e034816
    CrossrefPubMedSearch in Google Scholar
  • 28 Moncrieff J. Research on a ‘drug-centred’ approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs. Epidemiol Psychiatr Sci 2018; 27: 133-140
    CrossrefPubMedSearch in Google Scholar
  • 29 Mendel R, Hamann J, Traut-Mattausch E. et al. ‘What would you do if you were me, doctor?’: randomised trial of psychiatrists’ personal v. professional perspectives on treatment recommendations. Br J Psychiatry 2010; 197: 441-447
    CrossrefPubMedSearch in Google Scholar
  • 30 Guy A, Davies J, Rizq R. Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs. 2020 https://prescribeddrug.info/download/279/ Stand: 17.05.2021
    PubMedSearch in Google Scholar